Medexus Pharmaceuticals Inc stock forecast
Medexus Pharmaceuticals Inc (P731) Stock Forecast & Price Target
P731 Analyst Ratings
P731 Stock 12 Month Forecast
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| David Martin PhD | Bloom Burton | €3.81→€4.13 | buy | 15.43%Upside | Reiterated | 08/12/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| David Martin PhDBloom Burton | BuyReiterated€3.81→€4.13 | 08/12/26 | 15.43%Upside |
Best Analysts Covering Medexus Pharmaceuticals Inc
Copying David Martin PhD's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +9.28% per trade.
Copying David Martin PhD's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +47.46% per trade.
Copying David Martin PhD's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +85.79% per trade.
P731 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 2 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 2 | 1 | 1 | 0 |
In the current month, P731 has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. P731 average Analyst price target in the past 3 months is ―.
P731 Financial Forecast
P731 Earnings Forecast
Next quarter’s earnings estimate for P731 is EUR 0.06 with a range of EUR 0.05 to EUR 0.09. The previous quarter’s EPS was EUR 0.03. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
P731 Sales Forecast
Next quarter’s sales forecast for P731 is EUR 28.02M with a range of EUR 27.75M to EUR 28.38M. The previous quarter’s sales results were EUR 25.89M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

